|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-6-30
|
|
pubmed:abstractText |
Tamoxifen is widely used as endocrine therapy for oestrogen-receptor-positive breast cancer. However, many of these patients experience recurrence despite tamoxifen therapy by incompletely understood mechanisms. In the present report we propose that tamoxifen resistance may be due to differences in activity of metabolic enzymes as a result of genetic polymorphism. Cytochrome P450 2D6 (CYP2D6) and sulfotransferase 1A1 (SULT1A1) are polymorphic and are involved in the metabolism of tamoxifen. The CYP2D6*4 and SULT1A1*2 genotypes result in decreased enzyme activity. We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-10945602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-11037799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-11156380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-11415996,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-11972444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-12207635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-12419790,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-12419838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-12586780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-14652237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-16168100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-1978565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-2493433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-7053859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-8079382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-8142314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9012401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9023127,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9037249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9270005,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9345314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9808005,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15987423-9854023
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-542X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R284-90
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15987423-Adult,
pubmed-meshheading:15987423-Aged,
pubmed-meshheading:15987423-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15987423-Arylsulfotransferase,
pubmed-meshheading:15987423-Breast Neoplasms,
pubmed-meshheading:15987423-Chemotherapy, Adjuvant,
pubmed-meshheading:15987423-Cytochrome P-450 CYP2D6,
pubmed-meshheading:15987423-Female,
pubmed-meshheading:15987423-Genotype,
pubmed-meshheading:15987423-Humans,
pubmed-meshheading:15987423-Middle Aged,
pubmed-meshheading:15987423-Neoplasm Metastasis,
pubmed-meshheading:15987423-Polymerase Chain Reaction,
pubmed-meshheading:15987423-Polymorphism, Genetic,
pubmed-meshheading:15987423-Postmenopause,
pubmed-meshheading:15987423-Recurrence,
pubmed-meshheading:15987423-Risk Factors,
pubmed-meshheading:15987423-Sample Size,
pubmed-meshheading:15987423-Tamoxifen,
pubmed-meshheading:15987423-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
|
|
pubmed:affiliation |
Department of Biomedicine and Surgery, Division of Cellbiology, Faculty of Health Sciences, Linköping, Sweden. piapa@ibk.liu.se
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
